Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?
Beteiligte Einrichtungen
Bibliografische Daten
| Originalsprache | Englisch |
|---|---|
| ISSN | 0007-0963 |
| DOIs | |
| Status | Veröffentlicht - 10.2022 |
| PubMed | 35442535 |
|---|
